Archives

News

Collaborative innovation in biomedicine - June 22-23 - Washington DC

22 June 2009

This conference will cover key issues, challenges and best practices for Collaborative Innovation in Biomedicine, including: 

  • How to Create and Manage Consortia for Success
  • Data Contribution, Results Sharing and Enhancement Solutions
  • IP Issues for Consortia-Generated Knowledge
  • Moving from Pre-Competitive Collaboration Back into Competitive Programs
  • Case Studies of Leading Consortia 

Including Pharmaceutical Company Perspectives on Collaborative Innovation Consortia from:

Merck & Co. | Eli Lilly and Company | GlaxoSmithKline | Pfizer | Johnson & Johnson

 

Conference Program Advisors:

Dr. William B. Mattes, Director, Toxicology, Critical Path Institute

Dr. Elizabeth G. Walker, Assistant Director, Toxicology, Predictive Safety Testing Consortium, Critical Path Institute

Dr. Jackie Hunter, Senior Vice President, Science Environment Development, GlaxoSmithKline

Dr. Susie M. Stephens, I.T. Manager / Principal Research Scientist, Eli Lilly, Discovery I.T. Department, Eli Lilly and Company

 

For more information on the conference program and registration, please visit the Collaborative innovation in biomedicine confernce website.

 

 

« Return